Search
mipomersen (Kynamro)
Indications:
- homozygous familial hypercholesterolemia, as an adjunct to other anti-hyperlipidemic agent & diet
Adverse effects:
- injection-site reactions
- flu-like symptoms
- nausea
- headache
- elevated serum transaminases
- boxed warning for increased risk hepatotoxicity
Mechanism of action:
- blocks transcription of proteins by binding to mRNA
- lowers LDL cholesterol levels ~25%
- lowers serum apolipoprotein B, total cholesterol, & non-HDL cholesterol
Interactions
drug adverse effects of anti-hyperlipidemic agents
General
anti-hyperlipidemic agent
References
- FDA News Release: Jan. 29, 2013
FDA approves new orphan drug Kynamro to treat inherited
cholesterol disorder.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337195.htm